Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.
Views & Analysis Nine for 2019: Opportunities for pharma In the last Nine for 2019 article, we reflected on the major challenges that are sha
Views & Analysis Nine for 2019: Challenges impacting pharma As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.
News Reaction to MSD's UK exit as government tries to renew talks The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
